10x Genomics advances into emerging field of in situ analysis with two acquisitions (NASDAQ:TXG)
Continuing on its mission of mastering biology to advance human health, 10x Genomics (NASDAQ:TXG) to acquire ReadCoor for cash and stock consideration of $350M.
The announcement follows acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August.
As a result of these transactions, 10x Genomics will acquire over 110 patents and applications that cover multiple foundational In Situ analysis approaches.
These add to its already comprehensive patent portfolio of over 825 issued patents and applications.
Source: Press Release